Clinical characteristics of ovulation induction with human menopausal gonadotropins with and without leuprolide acetate in polycystic ovary syndrome.

Journal Article (Clinical Trial;Journal Article)

Ovulation induction in polycystic ovary syndrome (PCOS) with human menopausal gonadotropins (hMG) results in suboptimal cycle fecundity and frequently is complicated by ovarian hyperstimulation. The use of a gonadotropin releasing-hormone agonist (Gn-RH-a) with hMG induction of ovulation may improve the therapeutic outcome. In this prospective, randomized trial, 27 women with PCOS underwent a total of 25 cycles of hMG alone and 33 cycles with adjunctive GnRH-a (leuprolide) treatment. Premature luteinization was seen less frequently in the leuprolide-treated cycles than in cycles treated with hMG alone. There were no differences between the treatments in ovarian sensitivity to hMG. Cycle fecundity was 0.16 for hMG alone cycles, and 0.27 for leuprolide with hMG cycles, which were not statistically different. We conclude that the sensitivity of the PCOS ovary to hMG is not affected by 4 weeks of leuprolide pretreatment.

Full Text

Duke Authors

Cited Authors

  • Dodson, WC; Hughes, CL; Yancy, SE; Haney, AF

Published Date

  • December 1989

Published In

Volume / Issue

  • 52 / 6

Start / End Page

  • 915 - 918

PubMed ID

  • 2512181

International Standard Serial Number (ISSN)

  • 0015-0282

Digital Object Identifier (DOI)

  • 10.1016/s0015-0282(16)53151-3


  • eng

Conference Location

  • United States